NYU Langone Health

The Pancreatic Cancer Action Network and the Global Coalition for Adaptive Research Forge a Powerful Alliance to Accelerate Treatment Options for Pancreatic Cancer Patients

Retrieved on: 
Tuesday, January 9, 2024
Pancreatic Cancer Action Network, Patient, JD, Research, MD, Lead, MBA, Vutrisiran, Organization, Clinical trial, NYU Langone Health, Pancreatic cancer, Growth, Pharmaceutical industry

LOS ANGELES and LARKSPUR, Calif., Jan. 9, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization dedicated to fighting the world's toughest cancer, in collaboration with the Global Coalition for Adaptive Research (GCAR), today announced a strategic alliance to leverage features from Precision Promise — a PanCAN-sponsored, master protocol clinical trial platform to test multiple regimens in metastatic pancreatic cancer — to launch the next phase of this groundbreaking effort, a new master protocol for pancreatic cancer sponsored by GCAR. This effort aims to continue to accelerate research for new treatment options in pancreatic cancer, the third leading cause of cancer-related deaths in the United States.

Key Points: 
  • This effort aims to continue to accelerate research for new treatment options in pancreatic cancer, the third leading cause of cancer-related deaths in the United States.
  • "We are excited about GCAR's investment in pancreatic cancer and believe that GCAR's impressive track record of innovating, operationalizing, and implementing the modernization of new clinical trial designs will drive and accelerate progress for patients with pancreatic cancer."
  • The alliance between PanCAN and GCAR represents a dynamic synergy, harnessing the strengths of both organizations to accelerate pancreatic cancer research and bring new treatments to patients.
  • PanCAN's unparalleled disease expertise, relationships with the pancreatic cancer community, and PanCAN's Patient Services program will continue to be pivotal to the new study and ensure that patients understand their treatment options.

Lawrence Phillips, MD, FASNC, Installed as ASNC's President for 2024

Retrieved on: 
Monday, January 8, 2024
Editorial, Cardiology, Past, North Shore University Hospital, Master of Science, Message, Thomas Jefferson University, Doctor of Philosophy, NYU, Society, Health policy, News, NYU Langone Health, Moyamoya disease, Patient, Diagnosis, ASNC, Medicine, Journal, MHS, Medical imaging

FAIRFAX, Va., Jan. 8, 2024 /PRNewswire/ -- Lawrence Phillips, MD, FASNC, director of nuclear cardiology and medical director for outpatient cardiology at NYU Langone Health, was installed as president of the American Society of Nuclear Cardiology (ASNC). He will serve as leader of the organization for the next year. Dr. Phillips is an associate professor of medicine in the Leon H. Charney Division of Cardiology and associate director of the training program in cardiovascular diseases at NYU Grossman School of Medicine. He launched his presidential term with an editorial urging nuclear cardiology professionals to view their field as "a team sport" and embrace education and quality improvement efforts that will unlock the field's potential for the future. His President's Message is published online in the Journal of Nuclear Cardiology.

Key Points: 
  • FAIRFAX, Va., Jan. 8, 2024 /PRNewswire/ -- Lawrence Phillips, MD, FASNC, director of nuclear cardiology and medical director for outpatient cardiology at NYU Langone Health, was installed as president of the American Society of Nuclear Cardiology (ASNC).
  • His President's Message is published online in the Journal of Nuclear Cardiology.
  • He completed his internal medicine residency and cardiovascular training fellowship at North Shore University Hospital in New York.
  • For nuclear cardiology news, follow Dr. Phillips on X (formerly Twitter) at @LPhillipsMD and @MyASNC.

Seizures Identified as Potential Cause of Sudden Unexplained Death in Children

Retrieved on: 
Thursday, January 4, 2024
Psychiatry, Yale University, Epilepsy, Death, Sleep, MPH, Autopsy, Sudden death, Fever, Seizure, Motion, University, University of New Mexico, SUDC, History, Sound, Physician, Smoking, NYU, Febrile seizure, NYU Langone Health, SIDS, Patient, Stomach, Research, Forensic pathology, Bangladesh Technical Education Board, Generalized tonic–clonic seizure, Child, Pharmaceutical industry

Most are infants in what is referred to as sudden infant death syndrome, or SIDS, but 400 or more cases involve children aged 1 and older, and in what is called sudden unexplained death in children (SUDC).

Key Points: 
  • Most are infants in what is referred to as sudden infant death syndrome, or SIDS, but 400 or more cases involve children aged 1 and older, and in what is called sudden unexplained death in children (SUDC).
  • These seizures lasted less than 60 seconds and occurred within 30 minutes immediately prior to each child's death, say the study authors.
  • For decades, researchers have sought an explanation to sudden death events in children, noticing a link between those with a history of febrile seizures (seizures accompanied by fever).
  • Further research, Devinsky notes, is also needed to determine precisely how seizures with or without fever may induce sudden death.

World-Renowned Surgeon Joins NYU Langone Health as Division Director of Minimally Invasive and Specialty Gynecologic Surgery

Retrieved on: 
Wednesday, January 3, 2024
Hospital, Division, NYU Langone Health, Research, Minimally invasive procedure, NYU, University, Endometriosis, Patient, Reproductive Sciences, Gynaecology, Nursing

NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.

Key Points: 
  • NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.
  • In his new roles, Dr. Lee will oversee minimally invasive surgical services that treat common and complex gynecologic conditions at NYU Langone's Manhattan campus and NYU Langone Hospital—Brooklyn.
  • "I am dedicated to advancing the boundaries of minimally invasive gynecologic surgery, ensuring world-class, patient-centered care," said Dr. Lee.
  • "This is an exciting chapter and I look forward to contributing to the continued excellence in women's health care at NYU Langone."

NYU Grossman School of Medicine and Sarah Lawrence College Launch Graduate Genomics Degree Program

Retrieved on: 
Wednesday, January 3, 2024
Chakravarti, Genetic code, Multimedia, Student, NYU Langone Health, Problem solving, Doctor of Education, GPA, Science, Disease, Environment, Postgraduate education, NYU, Doctor of Philosophy, Education, Human genetics, Genetics, CGC, Knowledge, GHA, Physiology, Patient, Curriculum, Immersion, Sarah Lawrence College, Data science, Nursing

GHA trainees will develop skills in data science and hospital care, drawing on knowledge in human genetics and genomics, bioinformatics, and healthcare systems.

Key Points: 
  • GHA trainees will develop skills in data science and hospital care, drawing on knowledge in human genetics and genomics, bioinformatics, and healthcare systems.
  • "Our program was designed to meet the evolving needs of health care systems, health care professionals, and patients with respect to genetics," said Anna Cantor, MA, MS, CGC , co-director of the GHA Master's Program at NYU Grossman School of Medicine and program director of genetics education at the Center for Human Genetics and Genomics.
  • The program is also designed to advance the diversity of graduate education through recruitment, retention, and support of underrepresented groups.
  • Culminating in a degree from NYU's Graduate School of Arts and Sciences, the program is set to be typically completed in two years.

Acreage Announces Executive Leadership Transition

Retrieved on: 
Friday, December 8, 2023
NYU Langone Health, Interim, FP, Acreage Holdings, Finance, Management

“Philip has been an integral member of Acreage for a number of years, and we are very pleased to welcome him to the executive team,” said Dennis Curran, Chief Executive Officer and Chairman of Acreage.

Key Points: 
  • “Philip has been an integral member of Acreage for a number of years, and we are very pleased to welcome him to the executive team,” said Dennis Curran, Chief Executive Officer and Chairman of Acreage.
  • “Philip has demonstrated outstanding leadership and played a crucial role in several Company milestones, including the streamlining of our operations and recent enterprise resource planning rollout.
  • Philip has held leadership roles in financial planning & analysis at Blackrock and operational finance and controllership roles at NYU Langone Medical Center.
  • At Acreage, he has led the FP&A team and has contributed to various corporate development and strategic planning initiatives.

Walden Macht & Haran LLP Files Lawsuit Against NYU Langone Health on Behalf of World-Renowned Cancer Researcher for Unlawful Termination

Retrieved on: 
Friday, November 17, 2023
Hamas, NYU Langone Health, Harvard University, Terrorism, Research, Employment, Education, Organization, Hostage, Character, Travesty, Supreme court, Laura, Stanford University, Social media, Abramson, University, NYU, School, Trustee, MD, File, Cancer, Death, Overseer, Doctor of Philosophy, Suggestion, PCC, Bookkeeping, Medical device, Science, New York University

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.
  • Dr. Neel may be the first fired for pro-Israel and anti-antisemitic re-posts on X, the social media site formerly known as Twitter.
  • According to the lawsuit, Dr. Neel “became a political casualty of NYULH’s effort to terminate” the physician who posted pro-Hamas content.
  • Partner Milton Williams leads the Walden Macht & Haran team representing Dr. Neel and includes senior counsel Daniel Chirlin and associate James Meehan.

NYU Langone Health to adopt new Philips health technology solutions in multi-year partnership directed at patient safety, quality and outcomes

Retrieved on: 
Thursday, November 16, 2023
NYU Langone Health, Research, NYSE, Safety, Information, Organization, Emaa, Pathology, Science, PHG, Informatics, EMR, Patient, Medicine, AEX, Neurology, United, Vizient, Inc., Digital, CMS, NYU, News, Neurosurgery, Partnership, Medicare, MRI, MDIP, Health, Medical imaging, Pharmaceutical industry

With the new technologies, NYU Langone clinicians can collaborate in real-time, whether sharing pathology, imaging studies or patient data to support diagnostic confidence and tailor individualized care plans.

Key Points: 
  • With the new technologies, NYU Langone clinicians can collaborate in real-time, whether sharing pathology, imaging studies or patient data to support diagnostic confidence and tailor individualized care plans.
  • Supported by Philips’ innovation and leadership in health technology, NYU Langone’s industry-leading knowledge of the patient journey and care pathways can help push the boundaries of personalized care.
  • With this new partnership, NYU Langone Health will be adopting Philips’ IntelliSite Pathology solution, enterprise informatics, and AI-enabled diagnostic imaging technologies such as the Philips Lumify Handheld Ultrasound.
  • [1] As an institution, NYU Langone consistently receives top-quality and safety accolades from independent arbiters of patient care.

Thubrikar Aortic Valve Announces Authorization to Expand the TAVI-1 CE Mark Trial with the Precision 2™ Delivery Catheter

Retrieved on: 
Friday, December 15, 2023
Other Health, Other Philanthropy, Other Science, Pharmaceutical, Research, Venture Capital, Medical Devices, Fund Raising, Hospitals, Professional Services, Foundation, Philanthropy, Science, Clinical Trials, Cardiology, General Health, Biotechnology, Surgery, Health, NYU Langone Health, DRS, Pressure, Structural heart disease, Mortality, TAV, Patient, University Medical Center, Aortic valve, KCCQ, Stroke, TAVI, Competence, Freedom, Hospital, Mathematical optimization, Medical device, Bara Kodali

Thubrikar Aortic Valve, Inc. today announced authorization from the Competent Authority of Poland to expand the TAVI-1 CE Mark trial of the Optimum Transcatheter Aortic Valve Implantation System™ (Optimum TAVI System™).

Key Points: 
  • Thubrikar Aortic Valve, Inc. today announced authorization from the Competent Authority of Poland to expand the TAVI-1 CE Mark trial of the Optimum Transcatheter Aortic Valve Implantation System™ (Optimum TAVI System™).
  • The authorization allows for an additional 15 patients to be treated with the Optimum TAV™ using the Company’s 2nd-generation delivery catheter, the Precision 2™ Catheter.
  • It allows the Optimum TAV to be repositioned and recaptured for retrieval, if necessary, during the TAVI procedure.
  • Due to the innovative catheter design, the Optimum TAV’s short frame reorients as it is deployed in the diseased valve which results in automatic axial alignment of the valve.

Where Patients Live Impacts Whether They Pick Up Their Heart-Failure Medications

Retrieved on: 
Thursday, December 14, 2023
NYU Langone Health, JAMA Network Open, United States Census Bureau, Eugene Braunwald, Assistant, Research, Population health, Policy, Kidney disease, Risk, Disease, Insurance, Patient, Pharmacy, University, Heart failure, Robert A. Blecker, Health information management, Prescription, Blood, National Institutes of Health, NYU, Heart, MPH, Death, Poverty, Doctor of Philosophy, Columbia University, Diabetes, Bangladesh Technical Education Board, Unemployment, Transport, Pharmaceutical industry, Nursing, Adhikari, Cardiology, Medicine, RN, MD, Health

By contrast, fewer patients living in areas in the highest quarter (40%) did not do so.

Key Points: 
  • By contrast, fewer patients living in areas in the highest quarter (40%) did not do so.
  • Along these lines, the risk of not picking up these lifesaving medications was 11% higher for patients in neighborhoods with the lowest socioeconomic status than for those in areas of higher status.
  • This amount of disparity is important because even differences in medication adherence of 5% to 10% can result in increased risk of death.
  • She adds that the researchers intend to investigate ways to identify individual patients at highest risk for not taking their medications.